Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with Vectibix™ (panitumumab)

GlaxoSmithKline (GSK) would like to inform healthcare professionals of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with Vectibix™ (panitumumab). Based on data from a regular safety review, rare (≥1/10,000 to <1/1000 patients) cases of SJS and TEN have been reported in patients treated with Vectibix™. Healthcare professionals are advised to withhold or discontinue the use of Vectibix™ in their patients if SJS or TEN are suspected.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.